|
1
|
Chung JY, Park YC, Ye H and Wu H: All
TRAFs are not created equal: common and distinct molecular
mechanisms of TRAF-mediated signal transduction. J Cell Sci.
115:679–688. 2002.PubMed/NCBI
|
|
2
|
Rothe M, Wong SC, Henzel WJ and Goeddel
DV: A novel family of putative signal transducers associated with
the cytoplasmic domain of the 75 kDa tumor necrosis factor
receptor. Cell. 78:681–692. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xie P: TRAF molecules in cell signaling
and in human diseases. J Mol Signal. 8:72013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Regnier CH, Tomasetto C, Moog-Lutz C, et
al: Presence of a new conserved domain in CART1, a novel member of
the tumor necrosis factor receptor-associated protein family, which
is expressed in breast carcinoma. J Biol Chem. 270:25715–25721.
1995. View Article : Google Scholar
|
|
5
|
Camilleri-Broet S, Cremer I, Marmey B, et
al: TRAF4 overexpression is a common characteristic of human
carcinomas. Oncogene. 26:142–147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dews M, Homayouni A, Yu D, et al:
Augmentation of tumor angiogenesis by a Myc-activated microRNA
cluster. Nat Genet. 38:1060–1065. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El Baroudi M, Cora D, Bosia C, Osella M
and Caselle M: A curated database of miRNA mediated feed-forward
loops involving MYC as master regulator. PLoS One.
6:e147422011.PubMed/NCBI
|
|
9
|
Hermeking H: p53 enters the microRNA
world. Cancer Cell. 12:414–418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hermeking H: The miR-34 family in cancer
and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kole AJ, Swahari V, Hammond SM and
Deshmukh M: miR-29b is activated during neuronal maturation and
targets BH3-only genes to restrict apoptosis. Genes Dev.
25:125–130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park SY, Lee JH, Ha M, Nam JW and Kim VN:
miR-29 miRNAs activate p53 by targeting p85 α and CDC42. Nat Struct
Mol Biol. 16:23–29. 2009.PubMed/NCBI
|
|
13
|
Fabbri M, Garzon R, Cimmino A, et al:
MicroRNA-29 family reverts aberrant methylation in lung cancer by
targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA.
104:15805–15810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garzon R, Heaphy CE, Havelange V, et al:
MicroRNA 29b functions in acute myeloid leukemia. Blood.
114:5331–5341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mott JL, Kobayashi S, Bronk SF and Gores
GJ: mir-29 regulates Mcl-1 protein expression and apoptosis.
Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sengupta S, den Boon JA, Chen IH, et al:
MicroRNA 29c is down-regulated in nasopharyngeal carcinomas,
up-regulating mRNAs encoding extracellular matrix proteins. Proc
Natl Acad Sci USA. 105:5874–5878. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiong Y, Fang JH, Yun JP, et al: Effects
of microRNA-29 on apoptosis, tumorigenicity, and prognosis of
hepatocellular carcinoma. Hepatology. 51:836–845. 2010.PubMed/NCBI
|
|
18
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shiraishi T, Terada N, Zeng Y, et al:
Cancer/Testis Antigens as potential predictors of biochemical
recurrence of prostate cancer following radical prostatectomy. J
Transl Med. 9:1532011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshida T, Shiraishi T, Horinaka M, et al:
Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression
and sensitize malignant tumor cells to TRAIL-induced apoptosis.
Cancer Sci. 98:1417–1423. 2007. View Article : Google Scholar
|
|
22
|
Kedinger V and Rio MC: TRAF4, the unique
family member. Adv Exp Med Biol. 597:60–71. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kalkan T, Iwasaki Y, Park CY and Thomsen
GH: Tumor necrosis factor-receptor-associated factor-4 is a
positive regulator of transforming growth factor-β signaling that
affects neural crest formation. Mol Biol Cell. 20:3436–3450.
2009.PubMed/NCBI
|
|
24
|
Ye L, Lewis-Russell JM, Kyanaston HG and
Jiang WG: Bone morphogenetic proteins and their receptor signaling
in prostate cancer. Histol Histopathol. 22:1129–1147.
2007.PubMed/NCBI
|
|
25
|
Bubendorf L, Schopfer A, Wagner U, et al:
Metastatic patterns of prostate cancer: an autopsy study of 1,589
patients. Hum Pathol. 31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang TC, Yu D, Lee YS, et al: Widespread
microRNA repression by Myc contributes to tumorigenesis. Nat Genet.
40:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ellwood-Yen K, Graeber TG, Wongvipat J, et
al: Myc-driven murine prostate cancer shares molecular features
with human prostate tumors. Cancer Cell. 4:223–238. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hawksworth D, Ravindranath L, Chen Y, et
al: Overexpression of C-MYC oncogene in prostate cancer predicts
biochemical recurrence. Prostate Cancer Prostatic Dis. 13:311–315.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jenkins RB, Qian J, Lieber MM and Bostwick
DG: Detection of c-myc oncogene amplification and chromosomal
anomalies in metastatic prostatic carcinoma by fluorescence in situ
hybridization. Cancer Res. 57:524–531. 1997.PubMed/NCBI
|
|
30
|
Karin M: Nuclear factor-κB in cancer
development and progression. Nature. 441:431–436. 2006.
|
|
31
|
Ismail HA, Lessard L, Mes-Masson AM and
Saad F: Expression of NF-κB in prostate cancer lymph node
metastases. Prostate. 58:308–313. 2004.
|
|
32
|
Lessard L, Begin LR, Gleave ME, Mes-Masson
AM and Saad F: Nuclear localisation of nuclear factor-kappaB
transcription factors in prostate cancer: an immunohistochemical
study. Br J Cancer. 93:1019–1023. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lessard L, Karakiewicz PI, Bellon-Gagnon
P, et al: Nuclear localization of nuclear factor-kappaB p65 in
primary prostate tumors is highly predictive of pelvic lymph node
metastases. Clin Cancer Res. 12:5741–5745. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Setlur SR, Royce TE, Sboner A, et al:
Integrative microarray analysis of pathways dysregulated in
metastatic prostate cancer. Cancer Res. 67:10296–10303. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Esparza EM and Arch RH: TRAF4 functions as
an intermediate of GITR-induced NF-kappaB activation. Cell Mol Life
Sci. 61:3087–3092. 2004. View Article : Google Scholar : PubMed/NCBI
|
